Nihon Pharmaceutical · Polyclonal Antibodies · Polyclonal Antibodies
human normal immunoglobulin G is a polyclonal antibodies developed by Nihon Pharmaceutical. It is approved for therapeutic indications via injectable (others) or intravenous (iv).
| Brand Names | NPB01 |
| Company | Nihon Pharmaceutical |
| Drug Class | Polyclonal Antibodies, Antibody |
| Route | Injectable (Others), Intravenous (IV) |
| Status | Approved |
human normal immunoglobulin G is developed for 11 unique indications across 5 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Skin and subcutaneous tissue disorders | Erythema multiforme | ✓ Approved |
| Nervous system disorders | Guillain-Barre syndrome | ✓ Approved |
| Skin and subcutaneous tissue disorders | Pemphigoid | ✓ Approved |
| Skin and subcutaneous tissue disorders | Pemphigus | ✓ Approved |
| Infections and infestations | Salmonellosis | ✓ Approved |
+6 more indications available with a free account
Sign up free to view all indications →Smith-Norowitz Tamar A TA, Abdelmajid Haram H, Klein Elliot E, Joks Rauno R et al.
Dojcsák Dalma D, Ilosvai Ágnes Mária ÁM, Vanyorek László L, Váradi Csaba C
Magnetic nanoparticles (MNPs) are increasingly utilized in biomedical applications, including nucleic acid isolation, protein purification and glycan enrichment, owing to their high surface-to-volume ratio, tuneable surface chemistry and compatibility with automation. Here, we report the development, systematic optimization and automated implementation of an amine-functionalized NiFe2O4-based MNP protocol for N-glycan purification. Critical workflow steps, including particle drying and dispersion, binding efficiency, and elution buffer selection, were comprehensively evaluated. The optimized protocol, employing 0.5 mg/mL NiFe2O4-NH2 particles and 150 mM ammonium-formate (pH 4.4) as elution buffer enabled the reproducible identification of the major N-glycan peaks from human serum and immunoglobulin G (IgG). Importantly, the method was successfully translated to a Hamilton Microlab Prep robotic liquid handling platform in a 96-well format, ensuring scalability and reduced manual variability. Overall, this study advances a previously established MNP-based glycan purification approach into a robust, scalable, and automation-compatible workflow through synthesis redesign, systematic optimization, and successful robotic implementation.
El-Shenawy Fareed Sh FS, Abo-Dahab Nageh F NF, El-Wahsh Hossam H H HHH, Amara Amro A AA et al.
Arginase is a therapeutic enzyme with promising anticancer applications, driving the search for novel microbial producers for this enzyme with superior properties. Here, we report a new fungal strain, identified morphologically and genetically as Aspergillus niger AUMC16187 (GenBank: OR447698), isolated from soil as a potent arginase producer. The enzyme was purified to homogeneity via Sephadex G-50 gel filtration and characterized as a dimeric, thermostable metalloenzyme, most active at 40 °C and stable over a broad temperature range. Crucially, the purified arginase exhibited significant and selective cytotoxicity against human epidermoid carcinoma (A431) cells, with lesser effects on normal human skin fibroblasts (HSF). Its therapeutic effect was confirmed by flow cytometry. The unique combination of biochemical robustness and selective anticancer activity in this novel A. niger arginase underscores its high potential as a promising biocatalyst for targeted cancer therapy and other biomedical applications.
Jang Kyu Won KW, Choi Byung Hyun BH, Kim Il Young IY
Acute antibody-mediated rejection without detectable human leukocyte antigen donor-specific antibodies has been increasingly reported. We describe a case of antibody-mediated rejection associated with pre-existing anti-vimentin antibodies in a kidney transplant recipient with no detectable human leukocyte antigen donor-specific antibodies on Pretransplant evaluation. A non-human leukocyte antigen antibody panel identified anti-vimentin antibodies before transplantation. Despite treatment with methylprednisolone, plasmapheresis, intravenous immunoglobulin, and rituximab, antibody mediated rejection recurred and led to progressive graft dysfunction. This case underscores the importance of expanded pretransplant screening for preformed autoantibodies, particularly in recipients receiving long-term hemodialysis, and highlights the potential need for more intensive monitoring and management in patients with anti-vimentin antibodies.
Nakasako Junji J, Yaguchi Rena R, Terayama Atsushi A, Kuwahara Motoi M et al.
Effective treatments for amyotrophic lateral sclerosis (ALS) remain limited, underscoring the need to identify robust biomarkers associated with disease severity and prognosis. This study investigated whether immunoglobulin G (IgG) and immunoglobulin M (IgM) anti-glycolipid antibodies are associated with clinical manifestations of ALS, particularly decline in respiratory function. This was a retrospective observational cohort study of the patients with ALS. Among patients with definite or probable limb-onset ALS, 11 patients in the glycolipid IgG-positive group were compared with 15 patients in the IgG-negative group, and 5 patients in the glycolipid IgM-positive group were compared with 9 patients in the IgM-negative group, with adjustment for age. Associations between anti-glycolipid antibody status and respiratory function were assessed using Kaplan-Meier survival analysis and Cox proportional hazards models. The time to decline of percent forced vital capacity (%FVC) below 80% and 60% was significantly shorter in the IgG-positive group than in the IgG-negative group (p = 0.002 and p = 0.025, respectively). Cox proportional hazards analysis demonstrated that IgG antibody positivity was an independent risk factor for earlier decline in %FVC to 80%. These findings suggest that anti-glycolipid IgG antibodies may be associated with respiratory function decline in ALS. Larger comprehensive studies will be required to validate these results and to elucidate the underlying pathophysiological mechanisms.
Dos Anjos Santos Carolina Ávila CÁ, Pereira Arthur Van Lauter Albuquerque AVLA, Dos Santos Karla Crystina Costa KCC, da Silva Arthur Felix Freire AFF et al.
Amazonian biodiversity is an underexploited source of bioactive natural products with potential relevance to drug discovery for neglected diseases. Here, we characterized the chemistry and multi-target in vitro activity of an ethyl acetate extract from Dinizia excelsa wood. Extraction yielded 4.84 ± 0.10% and produced a phenolic-rich fraction with high total phenolics (501.8 ± 1.0mg GAE/g extract), flavonoids (172.4 ± 0.8mg QE/g), flavonols (49.7 ± 0.3mg QE/g), and hydrolyzable tannins (229.4 ± 1.2mg TAE/g). LC-HRMS dereplication annotated 19 metabolites, dominated by glycosylated flavonoids (rutin, isoquercetin), phenolic acids (ferulic and ellagic acids), ellagic derivatives (urolithins), and galloylated hydrolyzable tannins. The extract showed moderate-to-low antioxidant capacity across complementary assays (IC₅₀ 78.38-161.99µg/mL) and a favorable safety profile, with moderate/low cytotoxicity in mammalian cell lines (IC₅₀ 364-700µg/mL) and minimal hemolysis (<6% up to 1000µg/mL). In murine splenocytes, the extract preserved membrane integrity, induced dose-dependent proliferation, and promoted a broad but controlled cytokine response (↑IL-2, IL-4, IL-10, IL-12, IFN-γ, IL-17, TNF-α; regulated TGF-β), alongside reduced NO, mild cytosolic ROS modulation, and stable mitochondrial membrane potential. Notably, it displayed strong antiparasitic activity against Trypanosoma cruzi (IC₅₀ 2.37-3.94µg/mL) and Leishmania spp. (IC₅₀ 1.83-6.43µg/mL), with additional activity against Schistosoma mansoni (IC₅₀ 114.83-247.0µg/mL) and Plasmodium falciparum 3D7 (IC₅₀ 5438.27ng/mL). Antibacterial MICs ranged 16-512µg/mL and antifungal MICs 16-256µg/mL, consistent with bacteriostatic/fungistatic effects.
+9996 more articles available with a free account
Sign up free to view all articles →